StrideBio
StrideBio is a gene therapy company developing engineered AAV vectors using its proprietary STRIVE Capsid Platform to deliver genetic medicines for patients with life-threatening diseases. It is a pre-revenue, privately held biotech backed by strategic pharma and venture investors.
- Company typePrivate
- Founded2015
- HeadquartersDurham, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What StrideBio does
StrideBio is a gene therapy company founded in 2015 and headquartered in Durham, North Carolina, that develops engineered adeno-associated virus (AAV) vectors for the treatment of life-threatening genetic and neurological diseases. The company's core technology is the STRIVE Capsid Platform, a proprietary capsid engineering system intended to improve vector targeting, tissue specificity, and immune evasion in gene therapy delivery. StrideBio operates a Therapeutic Pipeline of gene therapy candidates built on this platform, supported by in-house AAV Manufacturing capabilities that provide vertical integration over vector supply and quality.
StrideBio serves patients with life-threatening diseases as its end-user population, while its primary commercial counterparties are pharmaceutical collaborators and equity capital providers. The company has raised approximately $97.2 million across three disclosed financing rounds (2017, 2018, 2021), with strategic pharma investors including Sarepta Therapeutics, Takeda Ventures, and UCB Ventures participating alongside venture capital firms such as Northpond Ventures, Novo Holdings, and Hatteras Venture Partners. The leadership team comprises CEO Mark Velleca, COO William Monteith, and co-founders Aravind Asokan and Mavis Agbandje, lending scientific and operational depth.
The business model is pre-revenue and dependent on equity financing and the prospective development of partnership, licensing, or product revenue as the pipeline advances. No pricing, licensing economics, or product commercialization has been disclosed, consistent with an early-stage biotech whose enterprise value is tied to platform validation, pipeline progression, and eventual clinical or commercial milestones rather than current sales. The company operates within the broader AAV vector manufacturing market, which is projected to grow from $1.03 billion in 2023 to $10.07 billion by 2034.
StrideBio firmographics
Firmographics- Name
- StrideBio
- Website
- https://stridebio.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- StrideBio is a gene therapy company developing engineered AAV vectors using its proprietary STRIVE Capsid Platform to deliver genetic medicines for patients with life-threatening diseases. It is a pre-revenue, privately held biotech backed by strategic pharma and venture investors.
- Ownership category
- akta.pro rank
StrideBio industry classification
Industry- Product category
- Gene Therapy Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
- akta.pro secondary industries
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)
Keywords
Where StrideBio is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Markets served
StrideBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain
StrideBio product offering
Product offeringCore offering
StrideBio develops engineered adeno-associated virus (AAV) vector-based gene therapies using its proprietary STRIVE™ Capsid Platform for targeted gene delivery. The company operates in-house AAV manufacturing to support its therapeutic pipeline of gene therapy candidates aimed at life-threatening genetic and neurological diseases.
Product overview
StrideBio is a gene therapy company developing a portfolio of treatments for life-threatening diseases. The company's offerings center around the STRIVETM Capsid Platform, which enables engineering of AAV vectors for targeted gene delivery, supported by internal AAV Manufacturing capabilities. The Therapeutic Pipeline represents the company's drug development candidates derived from this platform.
Differentiator
Problem solved
Functional benefit
Products and services
- STRIVE™ Capsid Platform
- Therapeutic Pipeline
- AAV Manufacturing
Companies that use StrideBio
Customer profileSegments1 record
Ideal customer profiles2 records
StrideBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
StrideBio partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights4 records
StrideBio competitors and assessment
Company assessmentDirect peers
- REGENXBIO: Clinical-stage AAV gene therapy company with proprietary NAV Technology platform for capsid engineering. Direct competitor in engineered AAV vectors for rare diseases and CNS indications, and a benchmark for platform-to-product translation.
- Voyager Therapeutics: Gene therapy company developing AAV-based treatments for CNS diseases, with a proprietary capsid discovery platform (TRACER). Closely comparable in capsid engineering focus, therapeutic area, and pipeline strategy.
- 4D Molecular Therapeutics: Clinical-stage AAV gene therapy company with a Therapeutic Vector Evolution platform for custom capsid design. Direct competitor in tissue-targeted AAV capsid engineering for ophthalmology, cardiology, and pulmonology.
- Capsida Biotherapeutics: Gene therapy company built around an engineered AAV capsid platform with CNS and neuromuscular focus. Closely comparable to StrideBio as a capsid-engineering-first company targeting similar indications.
- Affinia Therapeutics: Developer of rationally engineered AAV capsids and gene therapies for CNS and muscle diseases. Direct competitor in the capsid-engineering niche with comparable platform-to-pipeline structure.
- uniQure: Clinical-stage gene therapy company with both AAV and lentiviral platforms; one of the few gene therapy companies with a commercial product (Hemgenix). Comparable as an established AAV developer with manufacturing infrastructure.
- Passage Bio: Clinical-stage AAV gene therapy company focused on CNS disorders, with capsid selection tied to Penn/Gene Therapy Program collaborations. Comparable in AAV delivery focus and rare/CNS indication strategy.
- Solid Biosciences: Gene therapy company developing AAV-based treatments primarily for Duchenne muscular dystrophy and other neuromuscular diseases. Comparable in AAV delivery modality and rare-disease therapeutic focus.
- Taysha Gene Therapies: Clinical-stage AAV gene therapy company developing treatments for CNS and rare diseases, leveraging partnerships with UT Southwestern. Comparable in AAV delivery, indication focus, and platform-based pipeline approach.
Broad incumbents
- Sarepta Therapeutics: Commercial-stage leader in AAV-based gene therapy for Duchenne muscular dystrophy (Elevidys) and other neuromuscular diseases. Functions as both an investor in StrideBio and an incumbent benchmark for AAV gene therapy commercialization.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
StrideBio social profiles
Digital presenceStrideBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
StrideBio leadership team
Management profileNumber of profiles
Profiles5 records
StrideBio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
StrideBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about StrideBio
What does StrideBio do?
StrideBio develops engineered adeno-associated virus (AAV) vector-based gene therapies using its proprietary STRIVE™ Capsid Platform for targeted gene delivery. The company operates in-house AAV manufacturing to support its therapeutic pipeline of gene therapy candidates aimed at life-threatening genetic and neurological diseases.
Is StrideBio a public or private company?
StrideBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was StrideBio founded?
StrideBio was founded in 2015. It employs 51 to 100 people.
Where is StrideBio based?
StrideBio is headquartered in Durham, United States, in the North America region.
Who are StrideBio's main competitors?
Direct peers on record are REGENXBIO, Voyager Therapeutics, 4D Molecular Therapeutics, Capsida Biotherapeutics, Affinia Therapeutics, uniQure, Passage Bio, Solid Biosciences and Taysha Gene Therapies. Sarepta Therapeutics is listed as a broad incumbent.
Does StrideBio have an API?
No public API is recorded for StrideBio.
What industry is StrideBio in?
StrideBio's product category is Gene Therapy Development. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 2836.